Quantum BioPharma Doubles Liquidity to $11.2M, Files IND for Lucid-MS Phase II
Quantum BioPharma’s cash and digital assets more than doubled to US$9.8 million in Q1 2026, boosting total liquidity to US$11.2 million and securing a runway to July 2027. Operating cash burn fell 60% to US$1.66 million, and an IND application was filed for its Lucid-MS Phase II multiple sclerosis trial.
1. First Quarter 2026 Financial Results
As of March 31, 2026, combined cash, cash equivalents and digital assets totaled US$9.8 million, up from US$4.1 million at year-end 2025, with total liquidity reaching US$11.2 million. Operating cash use declined to US$1.66 million, a 60% drop year-over-year, driven by lower R&D fees following Phase I completion, extending runway to July 2027.
2. Lucid-MS Phase II IND Submission
Quantum formally submitted an IND application to the FDA for Lucid-MS, its first-in-class multiple sclerosis therapy, and appointed Dr. Salvatore Napoli as principal investigator. The company also signed a binding LOI with Allucent to conduct the planned Phase II clinical trial targeting demyelination.
3. Unbuzzd Corporate Reorganization
Unbuzzd completed its corporate reorganization and appointed a new CEO with capital markets experience to lead an IPO financing and nationwide commercialization. Quantum retains a 19.84% stake in Unbuzzd and will receive 7% royalties on sales until US$250 million is paid, then 3% thereafter.
4. Lawsuit Progress Against CIBC and RBC
Quantum’s memorandum opposing CIBC and RBC’s motion to dismiss was upheld by the U.S. District Court for the Southern District of New York. The ruling allows the company’s lawsuit alleging illegal market manipulation to proceed to discovery.